Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The use of intravenous immunoglobulin as maintenance therapy in myastheniagravis
Autore:
Hilkevich, O; Drory, VE; Chapman, J; Korczyn, AD;
Indirizzi:
Tel Aviv Univ, Sieratzki Chair Neurol, Dept Neurol, IL-69978 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-69978 Neurol, IL-69978 Tel Aviv, Israel
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 3, volume: 24, anno: 2001,
pagine: 173 - 176
SICI:
0362-5664(200105/06)24:3<173:TUOIIA>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
DISEASES; GLOBULIN;
Keywords:
intravenous immunoglobulin; myasthenia gravis; immunotherapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Korczyn, AD Tel Aviv Univ, Sieratzki Chair Neurol, Dept Neurol, IL-69978 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-69978 9978 Tel Aviv, Israel
Citazione:
O. Hilkevich et al., "The use of intravenous immunoglobulin as maintenance therapy in myastheniagravis", CLIN NEUROP, 24(3), 2001, pp. 173-176

Abstract

The standard therapy for myasthenia gravis (MG) includes steroids and immunosuppressants, which have delayed onset of action and significant side effects. Plasmapheresis and intravenous immunoglobulin have been used mostly for the treatment of severe exacerbations. In the present study we examined the use of intravenous immunoglobulin as maintenance treatment in MG. We included 11 patients with generalized myasthenia gravis. All had severe bulbar and respiratory involvement that required mechanical Ventilation in threepatients. Intravenous immunoglobulin treatment was initiated at a dose of 400 mg/kg/d for 5 days and followed by maintenance with 400 mg/kg once monthly. Regular medications were continued as necessary. There was significantimprovement in all patients, and none required mechanical ventilation overthe treatment period of 20.3 months +/- 8.3 (mean +/- SD, total patient years of treatment = 18.7). Steroid and pyridostigmine doses were reduced significantly and steroids were discontinued in two patients. There were no serious side effects related to intravenous immunoglobulin. These results suggest that intravenous immunoglobulin maintenance therapy is a valid modality in patients with MG.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 11:46:34